Topline Results

 
News Articles for Topline Results top ^
2015/1/12
SD-809 Met Primary Outcome Measure, Showed No Clinically Significant QT Prolongation LA JOLLA, Calif., Jan.
Sign-up for Auspex Announces Favorable Topline Results From Thorough QT Clinical Trial of SD-809 investment picks
2015/1/30
Nuvo Research® Reports Topline Results of Phase 2 Study of WF10™ for the Treatment of Allergic Rhinitis Canada NewsWire MISSISSAUGA, ON , Jan.
Sign-up for Nuvo Research® Reports Topline Results of Phase 2 Study of WF10™ for the Treatment of Allergic Rhinitis investment picks
2015/1/26
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced topline results for two double-blind phase III studies of Dysport ® (abobotulinumtoxinA) in Pediatric Lower Limb (PLL) spasticity in children with cerebral palsy and in Adult Lower Limb (ALL) spasticity in patients who had experienced a stroke or traumatic brain injury.
Sign-up for Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults investment picks
2015/2/3
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced topline results for two double-blind phase III studies of Dysport ® (abobotulinumtoxinA) in Pediatric Lower Limb (PLL) spasticity in children with cerebral palsy and in Adult Lower Limb (ALL) spasticity in patients who had experienced a stroke or traumatic brain injury.
Sign-up for Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults investment picks
2015/2/9
Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). ALKS 8700 is designed to rapidly and efficiently convert to MMF in the body and offer differentiated features as compared to the currently marketed dimethyl fumarate, TECFIDERA ® .
Sign-up for Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis investment picks
2014/12/16
Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated ARC-HD Trial Shows Successful Maintenance of Chorea Control After Switch to SD-809 NDA Submission Planned by Mid-2015 Conference Call Scheduled for 4:30 PM ET / 1:30 PM PT Today LA JOLLA, Calif., Dec.
Sign-up for Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease investment picks
2014/12/22
-- First-in-Class Drug Candidate to Prevent C.
Sign-up for Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection investment picks
2015/2/18
PALO ALTO, Calif., Feb.
Sign-up for Ocera Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study of OCR-002 investment picks
2015/1/9
Primary efficacy endpoints met in two trials of alirocumab administered every four weeks TARRYTOWN, N.Y. and PARIS , Jan.
Sign-up for Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia investment picks
2015/1/8
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background methotrexate in patients with moderate-to-severe rheumatoid arthritis (RA) did not meet its primary endpoint.
Sign-up for Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis investment picks
2015/1/30
- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET - MISSISSAUGA, ON , Jan.
Sign-up for Nuvo Research® Reports Topline Results of Phase 2 Study of WF10™ for the Treatment of Allergic Rhinitis investment picks
2015/2/17
-- Phase 2 Studies of VB-201 in Patients with Psoriasis and Ulcerative Colitis Did Not Meet Primary Endpoints --
Sign-up for VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis investment picks
2015/2/10
-- First-in-Class Drug Candidate to Prevent C.
Sign-up for Synthetic Biologics Announces Positive Topline Results from Phase 1b Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Topline Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Topics Companies  |  Next: Toronto Stock Exchange